BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 31074240)

  • 21. Long-Term Oncologic and Reproductive Outcomes in Young Women With Early Endometrial Cancer Conservatively Treated: A Prospective Study and Literature Update.
    Laurelli G; Falcone F; Gallo MS; Scala F; Losito S; Granata V; Cascella M; Greggi S
    Int J Gynecol Cancer; 2016 Nov; 26(9):1650-1657. PubMed ID: 27654262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review.
    Peng H; Jiang J; Li X
    Reprod Sci; 2022 Nov; 29(11):3278-3284. PubMed ID: 35641856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
    Simpson AN; Feigenberg T; Clarke BA; Gien LT; Ismiil N; Laframboise S; Massey C; Ferguson SE
    Gynecol Oncol; 2014 May; 133(2):229-33. PubMed ID: 24561246
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined medroxyprogesterone acetate/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer.
    Kim MK; Seong SJ; Kim YS; Song T; Kim ML; Yoon BS; Jun HS; Lee YH
    Am J Obstet Gynecol; 2013 Oct; 209(4):358.e1-4. PubMed ID: 23791687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful twin pregnancy achieved by assisted reproductive technology in a patient with polycystic ovary syndrome with complex atypical endometrial hyperplasia treated with levonorgestrel-releasing intrauterine system.
    Ercan CM; Duru NK; Sakinci M; Alanbay I; Karasahin KE; Baser I
    Gynecol Endocrinol; 2010 Feb; 26(2):125-8. PubMed ID: 20074021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma.
    Kudesia R; Singer T; Caputo TA; Holcomb KM; Kligman I; Rosenwaks Z; Gupta D
    Am J Obstet Gynecol; 2014 Mar; 210(3):255.e1-4. PubMed ID: 24211482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: A prospective, open-label, randomized controlled phase II study.
    Xu Z; Yang B; Shan W; Liao J; Shao W; Wu P; Zhou S; Ning C; Luo X; Zhu Q; Zhang H; Ma F; Guan J; Chen X
    Gynecol Oncol; 2023 Jul; 174():133-141. PubMed ID: 37182434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
    Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of dilatation & curettage and endometrial aspiration biopsy accuracy in patients treated with high-dose oral progestin plus levonorgestrel intrauterine system for early-stage endometrial cancer.
    Kim MK; Seong SJ; Song T; Kim ML; Yoon BS; Jun HS; Lee GH; Lee YH
    Gynecol Oncol; 2013 Sep; 130(3):470-3. PubMed ID: 23822890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report.
    Jiang J; Du H; Peng H
    Contraception; 2020 Dec; 102(6):428-429. PubMed ID: 32860769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
    Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
    Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
    Pal N; Broaddus RR; Urbauer DL; Balakrishnan N; Milbourne A; Schmeler KM; Meyer LA; Soliman PT; Lu KH; Ramirez PT; Ramondetta L; Bodurka DC; Westin SN
    Obstet Gynecol; 2018 Jan; 131(1):109-116. PubMed ID: 29215513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer: A Tertiary Center Experience.
    Shikeli S; Gowri V; Rawahi TA
    JBRA Assist Reprod; 2020 Oct; 24(4):466-469. PubMed ID: 32569453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009458. PubMed ID: 23737032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
    Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
    J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of levonorgestrel-releasing intrauterine device present during controlled ovarian stimulation in patients with early stage endometrioid adenocarcinoma and atypical endometrial hyperplasia after fertility-sparing treatments: 10-year experience in one tertiary hospital in China.
    Yin J; Li Y; Wang H; Wang W; Gu Y; Jin Y; Deng C; Pan L
    Eur J Obstet Gynecol Reprod Biol; 2023 Jan; 280():83-88. PubMed ID: 36436458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.